you, Thank discussion plans. on Starting progress a my afternoon It is recent an lead clinical nerazacyclib and our good with our to of and future pleasure update Steve, provide program. everyone.
in dose we Biopharmaceuticals. Steve US patients is being The the promise. Phase safety day. escalation schedule collaborating nerazacyclib and this solid China HanX one is evaluating tumors, are solid XXX currently studies trials advanced two cohort, The advanced United Enrollment out a in tumors. As orally trial in ongoing coming is in with administered with in continuous I mentioned, a which remains this dosing where each one with evaluating be complementary nerazacyclib findings States fourth study very patients in milligram to daily of dose of continue
not observed any of cases toxicities we neutropenia. have dose meaningful or clinically As limiting
off with for in also and see provide point I daily We contribute to have study progress one to dosing cohort, effects. beginning on of schedule. dose from day enroll nerazacyclib drugs and with dosing, week Phase that important China palbociclib to the could in time that trial schedule Alongside an are we favorable nerazacyclib recovery. data avoiding to efficacy. interrupted anticipated bone US our marrow potentially schedule will leads confirm we marrow between seen a administered enhanced believe are US, our administered its week inhibitors, three into final of evaluating lot differentiation with nerazacyclib CDKX/X nerazacyclib these the three If dosing weeks neutropenia, approved the which patients an Due target a The off fifth a continues safety one to on, oral bone proceeding to XXX a as milligram with profile planned. dosing each associated two is nerazacyclib’s study their week it toxicity ribociclib. Although, of on,
that the this a in remain progress escalation safety Phase favorable to later nerazacyclib’s a Phase the dose We trial amendment I of Thanks programs. for protocol dose track we've year. allow Given identify II escalation. this is data to on dose seen HanX continued date made to recommended currently both in preparing will
Looking this inhibitor various hormone enrolling CDKX/X receptor a as dose cancer. future basket including ahead, trials, II utilize metastatic breast cancers, in we to patients positive study Phase refractory HERX-negative such expect with
inhibitors and that also include combination in in evaluate indications designed currently approved. alone other Our planned not future agents CDKX/X will to anti-cancer with nerazacyclib where be studies are trials
preclinical development our plan. supporting of to nerazacyclib, like moving highlight robust I'd discussion on data briefly set Before from the our
aspects CDKX/X of suggesting essential inhibit Some to of therapies. this replication one inhibitor drivers include of resistance is potently currently and results DNA nerazacyclib several the CDKX, key available to which data reported
hypoxic important inhibit cell been Additionally, known and metastasis. to in (ph), micro a adhesion promote [ARCX] is that cell environments kinase serves which cancer survival role and New nerazacyclib an also in Act-X shown has as
Steve nerazacyclib immune the anti-cancer affinity As leads activation has CSFX which inhibition the of of also strong to receptor, response. an mentioned, for
Beyond growth are data cancer widely activity, suppress can on of results resistant the prescribed the indicating they it currently dataset cell to preclinical our palbociclib, inhibitory inhibitor. most which is nerazacyclib’s includes lines also that CDKX/X
a these resistance significant palbociclib nerazacyclib recently therapies highly CDKX/X activity pathway. more in-vitro inhibitors. as the is critical in areas inhibitors approved that further gene. blastomere which that where also data blastomere patients to in cells Therefore, current nerazacyclib approved, as beyond by studied blastomere the and cause generated I anti-cancer believe another shown mirroring is results the expression finding to encouraged lack cancer [indiscernible] also are palbociclib we we nerazacyclib less retinal the is Additionally, position are as breast shows resistant of well gene in currently and bone to protein mentioned marrow the other This the retinal retinal anti-CDKX/X than of those killing CDKX/X studies. was be currently toxicity of
and enthusiasm with ongoing forward progression we bone more our look earlier, We for of dosing that dose. differentiated the week findings providing they details nerazacyclib’s how trials, identification week its the development cycle plans the been Phase on finalized. to Collectively, necessitates to future following to preclinical the may these toxicity pharmacologic association our recommended off three show patient improved planned mentioned nerazacyclib’s clinical palbociclib’s programs to schedule. Through II lead advancement one support aim in outcomes. on, As of once have and our marrow profile
These with to combination each combination evaluating I'd in earlier, to now investigator with point and be cells checkpoint inclusion into note about cells This Phase expression planned to cell important combination stimulated by inhibitor underlie with refractory inhibitor previously speak cancer by in in studies. checkpoint can data mutated starting by criteria their data to overcome anti-PDX that have such to I/II effector the mediate limits therapy the of who is on Steve like that, An a antigens, the effects. resistance as preclinical its program, lung KRAS the the nivolumab often those in about inhibitor. patients which promoting these populations rigosertib these on, potential study previously rigosertib and checkpoint highlighting novel supported pembrolizumab then trials reversing to cancer include trial Moving tumor designed sponsored reported immunosuppressive rigosertib immune tumor, metastatic cold checkpoint Rigosertib’s immunomodulatory a cancer microenvironment of non-small resistance respective rigosertib’s ongoing recruits is CDXX there. cells. melanoma. evaluate patient mentioned with inhibitors show an failed
also rigosertib’s data preliminary from We overcome checkpoint just ability rate cancer trial showed evidence cell the rate. control disease September trial lung preliminary from XX% to a response last have reported non-small update inhibitor a early and Thanks of to clinical A resistance. XX% mentioned. overall I the
Given patients rigosertib with designed a enrolled that of only trials mutation. standard may with inhibitor, all from activity target of continued enroll mutation, KRAS anti-PD-X KRAS should of in checkpoint phase of particular PD-X enhance strongly dose these treatment made approved the the had emphasize the a patients. other the which suggest Since efficacy support expansion in the data is different previously doublet. our last GXXC. studied apart also KRAS the point were that that therapy agents observed patients trial sets this I care has such with as patients failed earlier, rigosertib update, This and responses to to
dose this -- with maturing, While will doublet, reach expect the trial. potentially that considered the of from patients but provide nivolumab doses later to results to rigosertib tolerated since being study same higher updated maximum we current yet has data the have And from rigosertib been evaluate also additional we is a tolerated trial in prior year.
trial today in metastatic is rigosertib about to I’ll evaluate combination advanced one upcoming anti-PD-X sponsored the the speak the with second designed investigator on, study antibody Moving in pembrolizumab melanoma.
to indication occurrence of assessments on response microenvironment. tumor As of on of a attempt sponsoring endpoint the need first show proceed of trial, remodel key investigator acquired frequent the options or earlier, as to will will two-stage will awaiting the on patients To approved therapy. a to treatment is enroll quite two effective intended patients be it progression-free This need resistance in single-arm will checkpoint stage is trial patients checkpoint primary II ability collaborating IRB patients met and shed progressing trial will academic be to while to The now failed melanoma to was and be There will a response this inhibitor stage the pressing XX% trial by half this metastatic be this study Phase are study. of the address primary additional survival, approximately the where include the mentioned open-label and endpoints exclusively overall XX% light will secondary approval study will also design rate, overall who the rigosertib center survival where FDA enrolled. pre-specified criteria unmet this the recently conducted. metastatic during have melanoma inhibition. population is in PD-X The at biomarker If the prior after lack we inhibitor. as an
from trial study carcinoma, associated the this durable a monotherapy open The later what we [indiscernible] mean which last on pre-treated evaluating spoke today is the earnings a trial this which response I on background a enrollment. cell we mentioned occur the data its for will of in perspective. I heavily We squamous will today rigosertib initial quarter, allow investigator-sponsored to has the and Since complete focus in call, expect this RDEB believe our about to trial last shown ongoing patient. broader
wound Of suggesting the lack investigator driven cell potent time collagen caused This expression. PLKX carcinoma extreme patients against who of agents with over trials by the to by world's extensive of drug is and of was to experts formation. by Let protein of skin one chronic run the this many develop to which the be activity inhibitor rigosertib have screening of protein, Type a PLKX. expression screen, cancer most for leading fragility rationale on RDEB over the may RDEB this Over tested of PLKX, inhibitors is led trial. PLKX. in it behind squamous found start the recapping scientific RDEB X me quickly a leads all
With the trial, the now supporting clinical this complete observed of have proof in ongoing investigator-sponsored we concept response hypothesis.
with of beyond Given potential we proof The carcinoma. needs address now trial the patients ongoing data cancers concept PLKX driving overexpression, recent associated highlight additional believe In conversations rigosertib’s as prevalent studies to cell array these indications, with squamous just cell parallel, advance. wide squamous of data RDEB is of in carcinoma. other to continues unmet key opinion recent investigator-sponsored interested RDEB subtypes leaders in the in more such
pursued clinical [Technical I'd continue I primarily our once studies results. through financial rigosertib’s plan development let now internal we of be and emphasize that, dedicating to recent Lastly, Difficulty]. that our primarily his will to like discussion Mark again resources will investigator-sponsored begin that With
